Malignant Pleural Effusion Clinical Trial
Official title:
A Randomized Phase II Trial of Primary Tumor Radiotherapy for Patients With Malignant Pleural Effusion Stage IV Non-Small Cell Lung Cancer
This randomized phase II study compare survival outcomes and toxicity of malignant pleural effusion stage IV non small-cell lung cancer patients Intrapleural infusion chemotherapy in combination with concurrent thoracic radiation therapy (TRT) VS not combination with concurrent thoracic radiation therapy (TRT).
Status | Recruiting |
Enrollment | 68 |
Est. completion date | December 30, 2021 |
Est. primary completion date | December 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients with pathological or cytological diagnosis, stage IV with malignant pleural effusion [UICC 2017 staging eighth edition] NSCLC patients; - initial treatment (previously did not receive any treatment), it is recommended to complete the detection of driver genes (EGFR / ALK / ROS1) (tissue, blood); - Age 18 to 80 years old, physical status score ECOG 0 to 2 or KPS = 70 (see Annex 2); Metastatic lesions in the distant area: conscious when brain metastasis; the number of metastatic lesions in the lung does not affect lung function and may be treated with primary and/or partial metastases; - no radiotherapy, EGFR-TKI and chemotherapy contraindications; - primary tumor radiotherapy requires IMRT technology; - Plan the design to give the primary tumor prescription dose (DTGTV) under the damage control threshold criteria; - The planned dose includes 100% GTV, 90% of the prescribed dose includes 98%~100% of PTV [planned target dose (DTPTV)]; normal lung (full lung volume minus GTV volume) V20 = 32%, MLD=20Gy; - metastatic tumor radiotherapy is a three-dimensional radiotherapy technique (IMRT/SRT/SBRT/VMAT, etc.), and large-segment radiotherapy. - Subjects have no major organ dysfunction, or laboratory test indicators must meet the following requirements: Hematology: normal range according to laboratory standards; cardiac function: normal range; liver function: normal range; renal function: normal range Lung function: FEV1>50%, impaired light-moderate lung function. - Informed consent (radiation, medication) before treatment; - The patient has good compliance with the treatment and follow-up received. Exclusion Criteria: - Patients who do not meet the pathological type, stage, and survival status of the inclusion criteria; - no malignant pleural effusion IV stage NSCLC; - patients with malignant pericardial effusion; Diffuse liver metastasis, intrapulmonary metastasis and has seriously affected patients with liver and lung function; - Patients with uncontrolled hypertension, diabetes, unstable angina, history of myocardial infarction, or symptomatic congestive heart failure or uncontrolled arrhythmias in the past 12 months; clinically diagnosed heart valve disease; • • •Active period of disease caused by bacteria, fungi or viruses; mental disorders; impaired severe lung function; - pregnant, lactating patients; - Patients with a history of other active malignancies other than small cell lung cancer before entering the group; non-melanoma skin basal cell carcinoma, in situ cervical cancer, and cured early prostate cancer; - Patients with allergies and no known alternatives to known or suspected drugs in any study; - Patients with poor compliance; - Researchers believe that it is not appropriate to participate in this test. |
Country | Name | City | State |
---|---|---|---|
China | Guizhou Cancer Hospital | Guiyang | Guizhou |
Lead Sponsor | Collaborator |
---|---|
Guizhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival(PFS) | PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. | up to 9 months | |
Secondary | Overall survival(OS) | Overall survival is defined as the time interval from date of diagnosis to date of death from any cause Overall survival is defined as the time interval from date of diagnosis to date of death from any cause Overall survival is defined as the time interval from date of diagnosis to date of death from any cause Overall survival is defined as the time interval from date of diagnosis to date of death from any cause Overall survival is defined as the time interval from date of diagnosis to date of death from any cause | Time Frame: up to 9 months | |
Secondary | Treatment toxicities | To assess and record nausea, vomiting, hematologic toxicity,radiation oesophagitis and other treantment complications by CTCAE v4.0 | Time Frame: up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT04793607 -
Interventions for Malignant Pleural Effusions Impact on Fatigue
|
||
Recruiting |
NCT02942043 -
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01997190 -
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT00564733 -
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04131231 -
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
|
N/A | |
Completed |
NCT02674243 -
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
|
Phase 3 | |
Terminated |
NCT01004510 -
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00313066 -
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
|
Phase 4 | |
Terminated |
NCT04236037 -
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
|
N/A | |
Completed |
NCT05372055 -
Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
|
||
Not yet recruiting |
NCT04914598 -
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
|
Phase 3 | |
Recruiting |
NCT04322136 -
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT03973957 -
Talc Outpatient Pleurodesis With Indwelling Catheter
|
N/A | |
Recruiting |
NCT05923515 -
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT02649894 -
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
|
N/A | |
Recruiting |
NCT03403855 -
Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients
|
N/A | |
Terminated |
NCT03597009 -
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
|
Phase 1/Phase 2 |